Taiwan Liposome Company, Ltd.

TLC BioSciences (Taiwan Liposome Company, Ltd.) is a clinical-stage biotechnology company that develops lipid-engineered medicines across metabolic, orthopedic, and immune-cell therapy areas. Its proprietary LipAD® family of platforms includes BioSeizer® sustained-release technology, NanoX® active drug-loading systems, and next-generation targeted lipid nanoparticles (tLNP). The pipeline spans once-monthly GLP-1 therapy (TLC518), late-stage non-opioid pain programs, and in-vivo CAR-T applications. The company was founded in 1997 by Dr. Keelung Hong and is headquartered in Nangang District, Taipei City, Taiwan.

TLC BioSciences was founded in 1997 by Dr. Keelung Hong, a liposome scientist who worked alongside Dr. Demetrios Papahadjopoulos and was involved in the development of the first FDA-approved liposomal drugs, Doxil and Onivyde. After co-founding a liposomal company in the United States, Dr. Hong established TLC in Taiwan. The company developed three approved liposomal drugs for oncology indications that were outlicensed for commercialization, and later shifted focus to orthopedics and pain management. Its pipeline includes late clinical-stage liposome solutions for osteoarthritis and postsurgical pain, as well as lipid nanoparticle candidates for cartilage protection and regeneration.

Pioneering once-monthly GLP-1, advanced pain therapeutics, and in-vivo CAR-T with next-generation lipid platforms.

• TLC599

  Late-stage non-opioid pain program for osteoarthritis

• TLC590

  Phase 3 trial for postsurgical pain

• TLC518

  Once-monthly GLP-1 therapy

• Ampholipad

  Approved liposomal drug

1. 1TLC BioSciences | HOMEtlcbio.com
2. 2TLC BioSciences | ABOUTtlcbio.com
3. 3TLC BioSciences | ABOUTtlcbio.com
4. 4TLC BioSciences | ABOUTtlcbio.com